Search results
Added:
2 years ago
Added:
2 years ago
Learn about the key take-home messages from ACC.22 with View from the Thoraxcenter hosts, Professor Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
In this succinct review video, they summarise the top late-breaking science trials and share their take on how the new data can be translated into practice.
Trials covered in detail include:
00:29: PACMAN AMI:…
View more
Added:
3 years ago
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of cardiac muscle with a heterogeneous clinical course.1 The disease is clinically characterised by left ventricular hypertrophy (LVH), which is typically asymmetric, and a subgroup of patients have left ventricular outflow tract obstruction (LVOTO) caused by systolic anterior motion (SAM) of the mitral valve leaflet(s).2,3 LVOTO is often…
View more
Added:
2 years ago
Learn more about of the top AHA 2021 late-breaking trialswith View from the Thoraxcenter hosts, Professor Nicolas Van Mieghem and DrJoost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL). In this short summary video, they summarise the take-home messages and share their take on how the data will shape patient care and research.
Trials covered in detail include:
• Aortic Valve Replacement versus…
View more
Added:
2 years ago
In this concise episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their analysis of the late-breaking trials that will be presented at ACC 2022.
Trials covered in detail include:
00:39: PACMAN AMI: Effects of Alirocumab on Coronary Atherosclerosis Assessed by Serial Multimodality Intracoronary Imaging in Patients…
View more